WIC
ACHN

Woodmont Investment Counsel’s Achillion Pharmaceuticals ACHN Stock Holding History

Woodmont Investment Counsel’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,500
Closed -$20K – 692
2016
Q3 		$20K Buy
+2,500
New +$21.3K 0.01% 368
2016
Q2 		– Sell
-2,500
Closed -$19K – 499
2016
Q1 		$19K Hold
2,500
– – 0.01% 346
2015
Q4 		$27K Hold
2,500
– – 0.01% 335
2015
Q3 		$17K Hold
2,500
– – 0.01% 368
2015
Q2 		$22K Buy
+2,500
New +$23.6K 0.01% 348

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Woodmont Investment Counsel's ACHN Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 2,500 shares — an estimated $20K sold.

Woodmont Investment Counsel first reported a position in ACHN in Q2 2015 and held it in 5 quarters. The position peaked at $27K in Q4 2015. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 2,500 Achillion Pharmaceuticals shares in Q4 2016, an estimated $20K.
  • Woodmont Investment Counsel first reported a position in Achillion Pharmaceuticals in Q2 2015 and held it in 5 quarters.
  • Woodmont Investment Counsel's Achillion Pharmaceuticals position peaked at $27K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.